Advertisement
Journal Home
Search for

Volume 40, Issue 1, Page 1 (January 2010)


View previous. 2 of 95 View next.

CT Angiography May Help Cut Mortality

MITCHEL L. ZOLER

Article Outline

My Take

Several Questions Still Lack Answers

Copyright

ORLANDO — Patients who had their coronary calcium levels imaged by CT angiography had substantially better survival than did similar patients who underwent standard management, an observational study has shown.

The findings, which involved more than 4,000 patients followed for more than 6 years, could have implications for insurance reimbursement of CT angiography, Dr. Matthew J. Budoff said at the annual scientific sessions of the American Heart Association. He hypothesized that the mortality difference between patients who underwent CT imaging and those who did not may be explained by improved compliance with therapy among patients who were able to see the extent of their calcified coronary disease.

Although several payers including United Healthcare, Aetna, Medicare, and Medicaid currently reimburse for CT angiography, the national policy of Blue Cross/Blue Shield is not to cover these examinations. The Blues' stated policy is that they will not cover new diagnostic tests until their value in improving patient outcomes is proved, Dr. Budoff said. He believes the new data mean this standard has now been met, but he acknowledged that the study was observational and not a prospective, randomized trial. Nonetheless, the size and duration of the study, as well as the striking magnitude of beneficial effect, should be persuasive, said Dr. Budoff, program director of cardiology at the Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center.

In his study, 2,538 symptomatic patients referred for assessment of possible coronary disease and evaluated by coronary CT had a 52% reduced risk of all-cause death during an average 6.7-year follow-up compared with a similar group of 1,706 patients whose work-up did not include CT angiography.

“Increased awareness of coronary artery disease severity among people undergoing CT angiography may have contributed to their survival,” Dr. Budoff said. “Probable mechanisms include increased adherence to and use of anti-atherosclerotic therapies, such as statins, angiotensin-converting enzyme inhibitors, and anti-platelet drugs” such as aspirin, he added.

Dr. Budoff shows patients in his clinic who undergo coronary CT and have coronary calcium six images of their coronary arteries that depict the calcium deposits and stenoses. “I think that this is something that leads to compliance. It's very black and white. Patients can see their plaque and stenosis and know they need treatment,” he said in an interview. Patients also receive their calcium scores.

The 4,244 symptomatic patients in the study had an average age of 58 years, and 62% did not have known coronary artery disease. The patients who underwent coronary CT and those who received standard care without coronary CT imaging were treated in the academic cardiology clinic at Harbor-UCLA.

The two groups were matched by age, gender, the time when they were first seen, and their conventional cardiac risk factors.

All patients undergoing coronary CT had the examination covered by their insurance providers; none of the patients paid for the exam out of pocket. One factor that the study did not control for was socioeconomic status. The patients who did not undergo CT angiography may have been, as a group, somewhat poorer than those who had CT examinations, Dr. Budoff said.

During an average 80-month follow-up, the all-cause mortality rate was 3% in patients who had CT examinations and 11% in those who did not, a statistically significant difference. Mortality rates began to diverge between the two groups after about 3 years, and then continued to diverge.

In a multivariate analysis that controlled for age, gender, and coronary risk factors, patients who had standard care had a fourfold higher risk of dying than did those who had CT angiography.

Dr. Budoff has served on the speakers bureau for GE, a company that markets CT equipment. None of his associates had any financial disclosures.


View full-size image.

Patients undergoing CT angiograms had the examination covered by their insurance; the other patients did not.

Courtesy Dr. Matthew J. Budoff


My Take 

return to Article Outline

Several Questions Still Lack Answers 

The study by Dr. Budoff contributes significantly to the growing number of studies that demonstrate the value of coronary CT. A 52% reduction in all-cause mortality over 6.7 years is impressive. A cost-benefit analysis would quite likely be favorable.

The fact that patients were shown images of their own coronary vasculature with objective evidence of disease is one potential compelling explanation of the results. Studies have shown repeatedly, however, that even among patients who have sustained myocardial infarction and have undergone coronary revascularization, compliance with life-saving medications can be shockingly low.

While providing a plausible explanation, the findings in this nonrandomized observational study need to be evaluated more precisely in a prospective fashion. While interesting, these results must be seen as hypothesis generating. There are many sources of confounding and bias that are not adequately addressed. For instance, did patients who underwent scanning have increased access to drugs, increased frequency of follow-up, more consistent lab testing, greater access to cardiac rehabilitation, better social support networks, etc.?

The standard for clinical trials is to have a randomized, controlled, prospective study. I consider it unlikely that this study will convince all health plans, especially federal ones, that coronary CT is the diagnostic tool of choice in patients with symptomatic coronary disease. Cost-effectiveness will have to be proven and the benefits of coronary CT, compared with conventional stress testing or angiography, will have to be further defined. Settling these issues will require a committed clinical trial that will probably have to be funded by the private sector.

DR. PETER P. TOTH is director of preventive cardiology at Sterling (Ill.) Rock Falls Clinic. He is also clinical associate professor at the University of Illinois, Peoria, and Southern Illinois University in Springfield. He reported having no conflicts of interest.

PII: S0300-7073(10)70002-5

doi:10.1016/S0300-7073(10)70002-5


View previous. 2 of 95 View next.